Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-Current Assets (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Non-Current Assets for 11 consecutive years, with $314.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 42.95% to $314.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, down 17.99% year-over-year, with the annual reading at $314.4 million for FY2025, 42.95% down from the prior year.
  • Non-Current Assets for Q4 2025 was $314.4 million at Intellia Therapeutics, down from $343.3 million in the prior quarter.
  • The five-year high for Non-Current Assets was $551.2 million in Q4 2024, with the low at $115.8 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $358.2 million, with a median of $362.7 million recorded in 2023.
  • The sharpest move saw Non-Current Assets soared 1129.61% in 2021, then plummeted 56.65% in 2022.
  • Over 5 years, Non-Current Assets stood at $525.2 million in 2021, then plummeted by 42.24% to $303.3 million in 2022, then dropped by 0.22% to $302.6 million in 2023, then soared by 82.11% to $551.2 million in 2024, then plummeted by 42.95% to $314.4 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $314.4 million, $343.3 million, and $402.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.